Live feed07:30:00·6mPRReleasevia QuantisnowCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting MinutesByQuantisnow·Wall Street's wire, on your screen.CGTX· Cognition Therapeutics Inc.Health Care
